Fourth ac­cel­er­at­ed ap­proval in Duchenne? Sarep­ta gets pri­or­i­ty re­view for gene ther­a­py amid FDA scruti­ny

Sarep­ta is once again on the ac­cel­er­at­ed ap­proval path for a Duchenne drug, pick­ing up a pri­or­i­ty re­view Mon­day morn­ing.

The FDA grant­ed the ac­cel­er­at­ed re­view to SRP-9001, Sarep­ta an­nounced Mon­day, which would be­come the biotech’s fourth Duchenne drug if ap­proved. Much like SRP-9001 will do, each of the pre­vi­ous three ther­a­pies went through the ac­cel­er­at­ed ap­proval path­way. But un­like the oth­ers, SRP-9001 is a gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER